hotspot -WSS

hotspot

author：focus 2025-08-04 03:40:02 - browse：46

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Palantir health business leans on meeting customers’ needs

entertainment

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Independent physicians launch a new lobbying group

It's time to get medical device identifiers over the finish line

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

FDA clears AI tool for detecting skin cancer

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Petition to FDA: Get the lead out of consumer hair dyes

Wildfire smoke exposes gaps in outdoor worker protections

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Continuity nursing helped my family in our darkest PICU moments

The tragedy of Johnson & Johnson’s Covid vaccine

Moonlake's readout produced a cash windfall. Risks remain

Retired US general questions alleged Putin, Prigozhin meeting

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Prior authorization will have to move faster under new Biden rule

focus

Why 40% Americans with Parkinson’s don’t see a neurologist

Copay coupons to count toward deductibles, after Biden court move

Parkinson’s finding may lead to tests and, someday, treatments

Biotech venture capitalists face new demands from investors

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Why 40% Americans with Parkinson’s don’t see a neurologist

leisure time

entertainment

focus

entertainment